An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy

Trial Profile

An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2013

At a glance

  • Drugs Volasertib (Primary)
  • Indications Bladder cancer; Renal cancer; Urethral cancer
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 27 Oct 2011 Actual number of patients (n= 50) reported by ClinicalTrials.gov
    • 19 Oct 2011 Status changed from active, no longer recruiting to completed on 1 Sep 2011 as reported by ClinicalTrials.gov
    • 04 May 2011 Planned end date changed from 1 Jun 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top